Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Employees

609

Sector

Biotechnology & Medical Research

Calendar

11:00am - Jefferies Global Healthcare Conference

More about the company

Quotes

Date	Price	Change	Volume
18/11/25	40.47 $	+0.80%	2,955,447
17/11/25	40.15 $	-2.69%	1,612,945
14/11/25	41.26 $	+0.29%	1,621,072
13/11/25	41.14 $	-0.68%	1,536,594
12/11/25	41.42 $	-0.19%	1,987,947

Delayed Quote Nasdaq, November 18, 2025 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

40.47USD

Average target price

48.83USD

Spread / Average Target

+20.67%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 18/11/2025 GMT			5-day change	1st Jan Change
40.47 ^USD	+0.80%		-2.48%	+115.27%

11-18	Sector Update: Health Care Stocks Rise Late Afternoon	MT
11-18	Sector Update: Health Care Stocks Higher Tuesday Afternoon	MT

Capitalization	5.6B 4.83B 4.47B 4.26B 7.84B 495B 8.61B 53.09B 20.51B 237B 20.98B 20.55B 870B	P/E ratio 2025 *	-714x	P/E ratio 2026 *	-15x
Enterprise value	4.66B 4.03B 3.73B 3.55B 6.53B 413B 7.17B 44.24B 17.09B 197B 17.48B 17.13B 725B	EV / Sales 2025 *	6.22x	EV / Sales 2026 *	11.8x
Free-Float	94.28%	Yield 2025 *	-	Yield 2026 *	-

11-18	Sector Update: Health Care Stocks Rise Late Afternoon	MT
11-18	Sector Update: Health Care Stocks Higher Tuesday Afternoon	MT
11-18	Arrowhead Pharmaceuticals Says FDA Approves Redemplo for Familial Chylomicronemia Syndrome Treatment	MT
11-18	Arrowhead Pharmaceuticals, Inc Announces FDA Approval of Redemplo to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome	CI
11-18	Arrowhead Pharmaceuticals Gets FDA Approval for Treatment for Familial Chylomicronemia Syndrome	DJ
11-18	Arrowhead Pharmaceuticals Shares Halted, Pending Material News Release	MT
11-18	US FDA approves Arrowhead's genetic disorder drug	RE
11-12	Arrowhead Has Large Market Opportunity With Severe Hypertriglyceridemia Treatment, Morgan Stanley Says	MT
11-12	Morgan Stanley Raises Price Target on Arrowhead Pharmaceuticals to $45 From $29, Keeps Equalweight Rating	MT
10-28	Arrowhead Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
10-22	B. Riley Raises Price Target on Arrowhead Pharmaceuticals to $61 From $38, Keeps Buy Rating	MT
10-21	Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis	CI
10-21	Arrowhead Pharmaceuticals Closes Licensing Deal With Novartis	MT

11-12	Arrowhead Has Large Market Opportunity With Severe Hypertriglyceridemia Treatment, Morgan Stanley Says	MT
11-12	Morgan Stanley Raises Price Target on Arrowhead Pharmaceuticals to $45 From $29, Keeps Equalweight Rating	MT
10-22	B. Riley Raises Price Target on Arrowhead Pharmaceuticals to $61 From $38, Keeps Buy Rating	MT
10-08	RBC Raises Price Target on Arrowhead Pharmaceuticals to $45 From $38, Keeps Outperform, Speculative Risk	MT
08-08	RBC Trims Price Target on Arrowhead Pharmaceuticals to $38 From $40, Keeps Outperform, Speculative Risk	MT

Arrowhead Pharmaceuticals, Inc. Share Price

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Valuation: Arrowhead Pharmaceuticals, Inc.

Chart: Arrowhead Pharmaceuticals, Inc.

Latest news: Arrowhead Pharmaceuticals, Inc.

Last Transcript: Arrowhead Pharmaceuticals, Inc.

Analysts' recommendations: Arrowhead Pharmaceuticals, Inc.

Press Releases: Arrowhead Pharmaceuticals, Inc.

News in other languages: Arrowhead Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Arrowhead Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

11-18	Arrowhead Pharmaceuticals : Redemplo Approval Conf Call Nov 2025 Final	PU
11-18	Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)	BU
11-06	Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results	BU
11-04	Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences	BU
10-28	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	BU

09-02	Novartis si assicura diritti di una terapia contro Parkinson
09-02	Novartis s'assure les droits d'une thérapie contre Parkinson
09-02	Novartis sichert sich Exklusivlizenz für Parkinson-Therapie von Arrowhead
09-02	Novartis erhält Lizenzrechte für Parkinson-Behandlung von Arrowhead
06-20	Adipositas: Muskelerhalt als neues Therapieziel

1 day	+0.80%
1 week	-2.48%
Current month	-4.53%
1 month	+9.94%
3 months	+103.26%
6 months	+157.61%
Current year	+115.27%

1 week	39.3	43.58
1 month	36.73	43.69
Current year	9.57	43.69
1 year	9.57	43.69
3 years	9.57	43.69
5 years	9.57	93.66
10 years	1.2	93.66

Manager	Title	Age	Since
Christopher Anzalone CEO	Chief Executive Officer	55	30/11/2007
Daniel J. Apel DFI	Director of Finance/CFO	-	12/05/2025
Peter Carignan CTO	Chief Tech/Sci/R&D Officer	-	31/07/2022

Director	Title	Age	Since
Christopher Anzalone CHM	Chairman	55	-
Mauro Ferrari BRD	Director/Board Member	65	18/08/2010
Michael Perry BRD	Director/Board Member	65	18/12/2011

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ARROWHEAD PHARMACEUTICALS, INC.	+0.80%	-2.48%	+112.78%	+31.74%	5.55B
ARGENX SE	-0.48%	+5.82%	+46.09%	+121.52%	56.25B
INSMED INCORPORATED	+2.14%	+4.09%	+202.69%	+933.95%	42.1B
WUXI APPTEC CO., LTD.	-1.54%	-1.21%	+74.62%	+7.41%	39.23B
BIONTECH SE	-0.14%	-5.63%	+0.65%	-38.38%	24.69B
GENMAB A/S	-3.01%	+2.16%	+32.14%	-38.43%	18.89B
WUXI BIOLOGICS (CAYMAN) INC.	-1.42%	-6.62%	+112.38%	-39.01%	17.08B
AKESO, INC.	-3.70%	-2.78%	+62.76%	+224.35%	13.77B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.09%	+5.13%	+169.10%	-	13.05B
SUMMIT THERAPEUTICS INC.	-0.83%	-12.27%	-11.43%	+1,617.76%	12.62B
Average	-0.83%	+0.65%	+80.18%	+313.43%	24.32B
Weighted average by Cap.	-0.58%	+1.74%	+82.84%	+294.49%

	2025 *	2026 *
Net sales	749M 647M 599M 570M 1.05B 66.32B 1.15B 7.11B 2.75B 31.71B 2.81B 2.75B 116B	386M 333M 309M 294M 540M 34.17B 594M 3.66B 1.41B 16.34B 1.45B 1.42B 60B
Net income	-4.64M -4M -3.71M -3.53M -6.49M -410M -7.13M -43.99M -16.99M -196M -17.39M -17.03M -721M	-372M -321M -297M -283M -521M -32.93B -572M -3.53B -1.36B -15.75B -1.39B -1.37B -57.83B
Net Debt	-933M -806M -746M -710M -1.31B -82.62B -1.44B -8.85B -3.42B -39.51B -3.5B -3.43B -145B	-1.02B -884M -819M -779M -1.43B -90.64B -1.58B -9.71B -3.75B -43.34B -3.84B -3.76B -159B